SCHEMBL20140382

SCHEMBL20140382

CCOC(=O)c1nc(CCC(F)(F)C(F)(F)F)c2ccccn12

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 3/20 0.44
ALDH1A1 P00352 6/20 0.43
KDM4E B2RXH2 5/20 0.43
HPGD P15428 4/20 0.43
GAA P10253 3/20 0.43
GLA P06280 1/20 0.43
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
CYP1A2 P05177 4/20 0.41
SMN1; SMN2 Q16637 4/20 0.41
CYP2C9 P11712 3/20 0.41
CYP2C19 P33261 3/20 0.41
NPSR1 Q6W5P4 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
CYP3A4 P08684 3/20 0.39
IDO1 P14902 2/20 0.39
HBB P68871 1/20 0.39
HIF1A Q16665 1/20 0.39
MEN1 O00255 3/20 0.37
KMT2A Q03164 3/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14776703 0.89 KDM4E (0.41) ALDH1A1KDM4EHPGDGAAGLA
SCHEMBL14776622 0.81 ALDH1A1 (0.48) MAPK1ALDH1A1KDM4EHPGDGAA
SCHEMBL14777105 0.78 CNR2 (0.34) CNR1CNR2
SCHEMBL4318706 0.74 KDM4E (0.54) MAPK1ALDH1A1KDM4EHPGDGAA
SCHEMBL2743126 0.74 CNR2 (0.61) MAPK1ALDH1A1KDM4EHPGDGAA
SCHEMBL4331034 0.73 MAPK1 (0.51) MAPK1ALDH1A1KDM4EHPGDGAA
SCHEMBL4321445 0.73 MAPK1 (0.51) MAPK1ALDH1A1KDM4EHPGDGAA
SCHEMBL31215223 0.73 HIF1A (0.53) MAPK1ALDH1A1KDM4EHPGDGAA
SCHEMBL4324403 0.72 CNR1 (0.60) MAPK1ALDH1A1KDM4EHPGDGAA
SCHEMBL4318781 0.71 ALDH1A1 (0.54) MAPK1ALDH1A1KDM4EHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435080-B2 sGC stimulators TISENTO THERAPEUTICS INC. (US) 2025-10-07 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-20220017515-A1 sGC STIMULATORS TISENTO THERAPEUTICS INC. 2022-01-20 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-11180493-B2 SGC stimulators CYCLERION THERAPEUTICS, INC. (US) 2021-11-23 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
US-20200071318-A1 SGC STIMULATORS TISENTO THERAPEUTICS INC. 2020-03-05 US disclosed
EP-3538520-A2 SGC STIMULATORS Cyclerion Therapeutics, Inc. (US) 2019-09-18 EP disclosed
WO-2018089330-A2 SGC STIMULATORS IRONWOOD PHARMACEUTICALS, INC. (US) 2018-05-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200071318-A1 SGC STIMULATORS GUCY1A2, GMPS, PDE2A MAPK1 895/4885ALDH1A1 2298/4885KDM4E 3627/4885
US-20220017515-A1 sGC STIMULATORS GUCY1A2, PRKG1, PDE2A MAPK1 853/4885ALDH1A1 2355/4885KDM4E 3552/4885
US-12435080-B2 sGC stimulators GUCY1A2, PRKG1, PDE2A MAPK1 853/4885ALDH1A1 2355/4885KDM4E 3552/4885
US-11180493-B2 SGC stimulators GUCY1A2, GMPS, PDE2A MAPK1 895/4885ALDH1A1 2298/4885KDM4E 3627/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.